NeoGenomics (NEO)
(Delayed Data from NSDQ)
$13.10 USD
-0.08 (-0.61%)
Updated Jun 17, 2024 04:00 PM ET
After-Market: $13.10 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
Brokerage Reports
0 items in cart
NeoGenomics, Inc. [NEO]
Reports for Purchase
Showing records 21 - 40 ( 132 total )
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
LIS Migration Causes Disruption in 4Q Long-Term Story Remains Attractive.
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
Updating Model for New Credit Facility, GE Stock Redemption, Light 4Q
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
Teach-In Discussion Highlights Integration Progress
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
CMS 2017 Final PFS - Reaffirms Proposed Rates with Slight Improvements
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
Solid 3Q Despite Significant Integration Efforts; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
Strong 2Q as Clarient Integration Progressing Nicely
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
CMS 2017 Preliminary Rule Inline with Expectations - Net Positive
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
Termination of Coverage-Analyst(s) Departure
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: GRISEWOOD S
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
Clarient Deal Transformative - Re- Initiating Coverage at Buy
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
Transferring Coverage
Provider: Roth Capital Partners, Inc.